Adenovirus-specific T cell therapy - Cell Medica

Drug Profile

Adenovirus-specific T cell therapy - Cell Medica

Alternative Names: ADV-specific T cell therapy - Cell Medica; Cytovir ADV

Latest Information Update: 07 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cell Medica
  • Class Cell therapies; T lymphocyte cell therapies
  • Mechanism of Action Cell replacements; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Adenovirus infections

Most Recent Events

  • 07 Aug 2018 Efficacy and adverse events data from a phase I/II ASPIRE trial in Adenovirus infections released by Cell Medica
  • 31 Dec 2016 Cell Medica completes a phase I/II ASPIRE trial in Adenovirus infections in United Kingdom (NCT01822093)
  • 03 Feb 2016 Phase-I/II development is ongoing in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top